Sensitivity analysis on a physiologically-based pharmacokinetic and pharmacodynamic model for diisopropylfluorophosphate-induced toxicity in mice and rats

被引:10
|
作者
Chen, Kaizhen [1 ]
Teo, Shiyi [1 ]
Seng, Kok -Yong [1 ]
机构
[1] DSO Natl Labs, Def Med & Environm Res Inst, Bioengn Lab, Singapore 117510, Singapore
关键词
Acetylcholinesterase; allometric scaling; diisopropylfluorophosphate; physiologically-based pharmacokinetic and pharmacodynamic model; sensitivity analysis; RISK-ASSESSMENT; INHIBITION; ACETYLCHOLINESTERASE; PLASMA; SOMAN; EXPOSURE; FORMS;
D O I
10.1080/15376510903300335
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model was recently developed to study the effect of diisopropylfluorophosphate (DFP) on acetylcholinesterase (AChE) activity in mouse and rat. That model takes into account relatively complex interactions involving many parameters, some of which may be uncertain and/or highly variable, especially those characterizing AChE activity after DFP intoxication. The primary objective of this study was to identify parameters that contribute most to the variability of AChE dynamics for model optimization against data. For this purpose, the influence of the variability of the rate constants for synthesis (K-syn) and degradation (K-deg) of AChE, and regeneration (K-reg) and aging (K-age) of inhibited AChE on the variability of AChE activity in mice and rat venous blood and brain was first calculated by a global sensitivity analysis. Next, the mouse PBPK/PD model was calibrated by optimizing the values of K-syn, K-deg, K-reg and K-age. Thereafter, scale-up of the DFP-induced AChE activity was performed from mouse to rat. Validation of the rat model was performed by comparing the time course of venous blood and brain AChE activities from a Monte Carlo analysis to those obtained in vivo. Sensitivity analysis on the verified models showed that K-reg and K-syn were the most influential factors of AChE activity at shorter and longer durations, respectively, after DFP challenge. Scale-up of the AChE dynamics from mouse to rat was also successful, as evidenced by significant overlapping between the predicted 95(th) percentile confidence intervals and the experimental data.
引用
收藏
页码:486 / 497
页数:12
相关论文
共 50 条
  • [41] Incorporation of the glutathione conjugation pathway in an updated physiologically-based pharmacokinetic model for perchloroethylene in mice
    Dalaijamts, Chimeddulam
    Cichocki, Joseph A.
    Luo, Yu-Syuan
    Rusyn, Ivan
    Chiu, Weihsueh A.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 352 : 142 - 152
  • [42] A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans
    Gao, Guanghua
    Law, Francis
    Wong, Ricky Ngok Shun
    Mak, Nai Ki
    Yang, Mildred Sze Ming
    ADMET AND DMPK, 2019, 7 (01): : 22 - 43
  • [43] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS IN TOXICITY TESTING AND RISK ASSESSMENT
    Lipscomb, John C.
    Haddad, Sami
    Poet, Torka
    Krishnan, Kannan
    NEW TECHNOLOGIES FOR TOXICITY TESTING, 2012, 745 : 76 - 95
  • [44] CHLOROPENTAFLUOROBENZENE - SHORT-TERM INHALATION TOXICITY, GENOTOXICITY AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL DEVELOPMENT
    KINKEAD, ER
    WALL, HG
    HIXSON, CJ
    TICE, RR
    KUTZMAN, RS
    VINEGAR, A
    TOXICOLOGY AND INDUSTRIAL HEALTH, 1990, 6 (06) : 533 - 550
  • [45] Bayesian calibration of carbaryl cholinesterase inhibition using physiologically-based pharmacokinetic and pharmacodynamic modeling
    Nong, Andy
    Yoon, Miyoung
    Clewell, Harvey J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [46] Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
    Liu, Hongrui
    Yu, Yiqun
    Liu, Lu
    Wang, Chunyan
    Guo, Nan
    Wang, Xiaojuan
    Xiang, Xiaoqiang
    Han, Bing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling of Unfractionated Heparin to Predict Activated Clotting Time
    Regorda, Filippo
    Vigoni, Emiliano
    Pesenti, Giuseppe
    Pieri, Marina
    Belletti, Alessandro
    Manca, Davide
    30TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING, PTS A-C, 2020, 48 : 703 - 708
  • [48] Characterizing the abuse potential of loperamide via physiologically-based pharmacokinetic/pharmacodynamic modeling and simulation
    Ainslie, Garrett
    Kharasch, Evan
    Pollack, Gary
    Paine, Mary
    FASEB JOURNAL, 2014, 28 (01):
  • [49] PHYSIOLOGICALLY-BASED PHARMACOKINETIC AND PHARMACODYNAMIC MODELING IN HEALTH RISK ASSESSMENT AND CHARACTERIZATION OF HAZARDOUS SUBSTANCES
    LEUNG, HW
    PAUSTENBACH, DJ
    TOXICOLOGY LETTERS, 1995, 79 (1-3) : 55 - 65
  • [50] Use of sensitivity analysis on a physiologically based pharmacokinetic (PBPK) model for chloroform in rats to determine age-related toxicity.
    Eklund, CR
    Simmons, JE
    Evans, MV
    TOXICOLOGICAL SCIENCES, 2003, 72 : 182 - 182